PAK1 and breast cancer: This Pak1 inhibitory domain (PID) can be used to block Pak1 activity and the biological effects of Pak1 signaling, such as the dissociation of Rac from RhoGDI [18,19], GPCR-dependent cell transformation and estrogen-dependent transcription in breast cancer cells [20,21].